Drug Approval | April 28, 2025
CuraTeQ Biologics receives positive opinion for biosimilar Dazublys from EMA
Trastuzumab specifically binds and inhibits the human epidermal growth factor receptor 2 (HER2) protein
Trastuzumab specifically binds and inhibits the human epidermal growth factor receptor 2 (HER2) protein
Multiple studies show the combination potential of vedotin antibody-drug conjugates (ADCs) with pembrolizumab, including the first Phase 1 data in thoracic cancers for two first-in-class ADCs
The capital raise will also support debt repayment or prepayment, improving the company's debt-to-equity ratio and overall financial resilience
SmartTrack aims to reduce the need for clinical studies in generic drug product approvals
Blenrep combinations could redefine treatment as early as first relapse where more effective options are needed
Genomics is transforming the future of modern medicine and treatment modalities across specialties
Centre for Continuous Manufacturing and Advanced Crystallisation (CMAC) aims to accelerate the digital transformation of CMC development and manufacturing approaches
Expanded US manufacturing and R&D presence with investment in 10 facilities, including 7 brand new facilities
The supply of these goods is set to commence within the first quarter of FY26
Fexuprazan has the longest half-life of 9 hours among potassium-competitive acid blockers
Subscribe To Our Newsletter & Stay Updated
